Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): forging a new alliance

Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of SCCHN namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum sensitive recurrent or metastatic disease in the first...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Cancer Ther
Asıl Yazarlar: Saba, Nabil F, Chen, Zhuo Gerogia, Haigentz, Missak, Bossi, Paolo, Rinaldo, Alessandra, Rodrigo, Juan P, Mäkitie, Antti A., Takes, Robert P, Strojan, Primoz, Vermorken, Jan B, Ferlito, Alfio
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6830522/
https://ncbi.nlm.nih.gov/pubmed/31676542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0214
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller